Pendal Group’s Haemonetics HAE Stock Holding History

Pendal Group’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-4,602	Closed	-$412K	–	465
2020 Q2	$412K	Buy	+4,602	New	+$465K	0.01%	342
2020 Q1	–	Sell	-727	Closed	-$83.5K	–	452
2019 Q4	$83.5K	Buy	+727	New	+$88K	﹤0.01%	422

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pendal Group's HAE Position: Q3 2020 in Review

Pendal Group sold out of Haemonetics (HAE) in Q3 2020, closing a stake of 4,602 shares — an estimated $412K sold.

Pendal Group first reported a position in HAE in Q4 2019 and held it in 2 quarters. The position peaked at $412K in Q2 2020. 268 funds tracked by Wall St. Rank hold HAE as of Q3 2020.

Pendal Group reported no remaining Haemonetics position as of Q3 2020 after selling out during the quarter.
Pendal Group sold 4,602 Haemonetics shares in Q3 2020, an estimated $412K.
Pendal Group first reported a position in Haemonetics in Q4 2019 and held it in 2 quarters.
Pendal Group's Haemonetics position peaked at $412K in Q2 2020.
268 funds tracked by Wall St. Rank held Haemonetics as of Q3 2020.

Based on Pendal Group's 13F filing for Q3 2020, filed 2 Nov 2020.